 Lipocine Inc. Nasdaq: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food Drug Administration FDA has accepted the Companys Investigational New Drug application IND to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic potential of LPCN 1148, an oral prodrug of bioidentical testosterone, for the treatment of liver cirrhosis in adult male cirrhotic patients. The planned Phase 2 clinical study is a prospective, multi-center, randomized, placebo-controlled 52-week study in male cirrhotic patients that are on the liver transplant list. Contingent upon available funding, Lipocine projects study initiation in the fourth quarter of 2020 or the first quarter of 2021. 